Nuvectis Pharma (NVCT) Net Equity Issued and Repurchased (2021 - 2026)

Nuvectis Pharma has reported Net Equity Issued and Repurchased for 5 years, with the latest figure at $7000.0 in Q1 2026.

• Quarterly Net Equity Issued and Repurchased fell 99.45% year-over-year to $7000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.3 million (up 69.5% YoY) and the FY2025 annual result came in at $15.7 million, up 30.44% from the prior year.
• Net Equity Issued and Repurchased fell to $7000.0 in Q1 2026 per NVCT's latest filing, from $175000.0 in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $13.5 million in Q3 2025 and troughed at $7000.0 in Q1 2026.
• A 4-year average of $2.7 million and a median of $1.3 million in 2025 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2025 and 2026: Net Equity Issued and Repurchased jumped 800.0% in 2025, then sank 99.45% in 2026.
• Over 4 years, Net Equity Issued and Repurchased stood at $901000.0 in 2023, then soared by 338.73% to $4.0 million in 2024, then tumbled by 95.57% to $175000.0 in 2025, then plunged by 96.0% to $7000.0 in 2026.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $7000.0, $175000.0, and $13.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.